Last week, VeloSano announced at the VeloSano Bash: Revealing the Cash celebration that the 2018 event raised a total of $4,513,293 for cancer research at Cleveland Clinic. The year-round fundraising initiative surrounding an annual "bike to cure" weekend is known for directing 100% of dollars raised to research efforts across the organization. " Our goal remains to discover more about the causes of cancer and develop better ways to treat it, with the ultimate goal of discovering a cure. We remain humbled and thankful for the support of VeloSano," said Brian J. Bolwell, MD, FACP, chairman of Cleveland Clinic's Taussig Cancer Institute, professor of medicine at Case Western Reserve University and deputy director for Cleveland Clinic, Case Comprehensive Cancer Center (Case CCC).

In the event's fifth year, the Case CCC team was recognized in the top 15 fundraising teams, bringing in a total of $62,636. Several members of the Center were also recognized for top individual fundraising accomplishments including those who rode "virtually." We are looking forward to next year's event, scheduled for July 19-21, and will provide additional information as registration opens for VeloSano 6 next month. Details about VeloSano Pilot Award RFAs will be provided in future Case CCC newsletters.  more>

Program Director of Pediatric Hematology and Oncology at University Hospitals Cleveland Medical Center, professor of pediatrics at Case Western Reserve University's School of Medicine, and leader of the  C ase

same tumor type permits the optimization of care by the creation of 'baskets' of individuals that are more similar and therefore more likely to respond to specific agents ( e.g.  EGFR activating mutations and tyrosine kinase inhibitors) However, despite impressive initial clinical responses, there is variability in the extent of response even within homogeneous 'baskets' and resistance to targeted therapies ultimately ensues. The extent that these failures are attributed to the topographic differences in genomes within tumors, or  intra tumoral heterogeneity, remains poorly studied," said Abazeed.

Nov 16, 12p | WRB Auditorium

Join us Friday, November 16 at 12p in the WRB Auditorium to hear K halid Sossey-Alaoui, PhD present " Regulation of the tumor microenvironment by

Kindlin-2 in breast cancer. "  Dr. Sossey-Alaoui is project staff, molecular cardiology at Cleveland Clinic, assistant professor of molecular medicine and member, Case Comprehensive Cancer Center at Case Western Reserve University.

His team is using  a multidisciplinary approach to investigate  how a ctin cytoskeleton - remodeling proteins ,  WAVE3 and Kindlins  regulate the invasion - metastasis cascade i n  breast cancer. more>

Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)

Deadlines:  April 15, 2019; April 15, 2020; April 15, 2021

The X02 pre-application is the highly-recommended first step in the U01 cooperative agreement application process.

Major changes from the previous FOAs (for X02s and U01s) under this program include:

• Max project period increased to 5 years from 4 years
• Patients must be seen at the NIH Clinical Center
• Clinical Center costs no longer charged to the grant except for the cost of drugs that are the subject of the study
• A single Institutional Review Board required for any multi-site study that will use the same protocol to conduct non-exempt human subjects research at more than one domestic site
• Clinical center Office of Regulatory Support can provide consultation on issues related to regulatory requirements, protocol navigation and attaining approvals

Opportunities for Fiscal Year 2019 related to the Cancer Moonshot

The National Cancer Institute has released 

information about new funding opportunities for Fiscal Year 2019 related to the Cancer Moonshot.

They may be supported with existing funds or with the 21st Century Cures funding. Click here for a complete list of open funding opportunity announcements.